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Background. Although tenofovir disoproxil fumarate (TDF) use has increased as part of first-line antiretroviral ther-
apy (ART) across sub-Saharan Africa, renal outcomes among patients receiving TDF remain poorly understood. We as-
sessed changes in renal function andmortality in patients starting TDF- or non–TDF-containing ART in Lusaka, Zambia.
Methods. We included patients aged ≥16 years who started ART from 2007 onward, with documented baseline
weight and serum creatinine. Renal dysfunction was categorized as mild (estimated glomerular filtration rate [eGFR],
60–89 mL/min), moderate (30–59 mL/min), or severe (<30 mL/min) according to the chronic kidney disease–
epidemiology (CKD-EPI) formula. Differences in eGFR during ARTwere analyzed using linear mixed-effect models.
The odds of developing moderate or severe eGFR decrease and mortality were assessed using logistic and competing
risk regression, respectively.
Results. We included 62 230 adults, of which 38 716 (62.2%) initiated a TDF-based regimen. The proportion
with moderate or severe renal dysfunction at baseline was lower in the TDF than in the non-TDF group (1.9% vs
4.0%). Among patients with no or mild renal dysfunction, those receiving TDF were more likely to develop moderate
(adjusted odds ratio, 3.11; 95% confidence interval, 2.52–3.87) or severe ( 2.43; 1.80–3.28) eGFR decrease, although
the incidence in such episodes was low. Among patients with moderate or severe renal dysfunction at baseline, renal
function improved independently of ART regimen, and mortality rates were similar in both treatment groups.
Conclusions. TDF use did not attenuate renal function recovery or increase the mortality rate in patients with
renal dysfunction. Further studies are needed to determine the role of routine renal function monitoring before and
during ART use in Africa.
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In 2007, Zambia was one of the first countries in sub-
Saharan Africa (SSA) to introduce tenofovir disoproxil
fumarate (TDF) as a preferred nucleotide reverse-
transcriptase inhibitor of first line antiretroviral therapy
(ART) [1, 2]. The advantages of TDF include its high
potency against human immunodeficiency virus
(HIV) and hepatitis B infections, favorable resistance
profile, good tolerability and safety, and availability as
a coformulation with other antiretroviral agents in
once-daily pills [3–5]. However, in industrialized coun-
tries, TDF has been associated with nephrotoxicity, in-
cluding proximal tubulopathy and impaired glomerular
filtration [6–11]. In SSA, a significant number of HIV-
infected patients start ART with preexisting kidney dys-
function, due to either HIV-associated nephropathy or
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other causes such as hypertension or diabetes [12, 13]. Although
the incidence of TDF-related kidney dysfunction seems to be low
inmost settings [8–10,14], the effect of TDF on clinical outcomes
in patients starting ART with moderate or severe renal dysfunc-
tion has not been studied previously, to our knowledge. In this
report, we evaluated changes in renal function and mortality in
patients starting TDF- or non–TDF-containing ART regimens
in a large cohort of HIV infected adults in Lusaka, Zambia.
METHODS
Zambian National HIV Program
Care and treatment provided through the Zambian National
HIV Program has been described elsewhere [15]. Along with
a detailed medical history and physical examination, the base-
line screening includes CD4 cell count and hemoglobin, serum
creatinine, and aminotransferase levels. The choice of ART de-
pends on laboratory test results, age and comorbid conditions.
Before June 2007, stavudine (d4T) or zidovudine (AZT) with
lamivudine (3TC) plus a nonnucleoside reverse-transcriptase
inhibitor, either nevirapine (NVP) or efavirenz (EFV), were
the recommended first-line agents. Thereafter, TDF replaced
d4T and AZT as the preferred nucleotide reverse-transcriptase
inhibitor alongside 3TC for patients with a creatinine clearance
level ≥50 mL/min. However, because creatinine clearance was
not calculated routinely, TDF was prescribed in patients with
a serum creatinine level ≤120 µmol/L. For those with impaired
renal function, abacavir (ABC) was prescribed instead of TDF.
Routine clinical follow-up visits were done every 3–6 months,
and TDF was substituted with ABC in patients in whom severe
renal dysfunction developed. Deaths are ascertained when re-
ported by a family member, clinic staff member, or community
health worker. Patient medical information is entered into an
electronic database for clinical care, monitoring and evaluation,
and reporting purposes [16]. These programmatic data have re-
ceived local ethical approval for use in the International epide-
miological Databases to Evaluate AIDS in Southern Africa
(IeDEA-SA) network, a large regional collaboration of ART
programs [17].
Inclusion Criteria, Definitions, and Outcomes
We included patients aged ≥16 years who started ART in the
capital city of Lusaka from June 2007, when the Zambian gov-
ernment instituted its national policy to incorporate TDF into
first-line ART [1]. Those without documented serum creatinine
and weight at baseline were excluded from the analysis cohort.
Owing to a lag in rollout of national ART guidelines, not all
the patients enrolled after June 2007 started a TDF-containing
ART regimen. We categorized first-line regimens as either
TDF–containing regimens (TDF + XTC [3TC or emtricitabine
(FTC)] + NVP or EFV) or non–TDF-containing regimens
(ABC or d4T or AZT + 3TC +NVP or EFV). Although boosted
protease inhibitors (bPIs) may be incorporated into first-line
regimens after nonnucleoside reverse-transcriptase inhibitor in-
tolerance, they are typically reserved for second-line therapy
and are almost never prescribed at ART initiation. In addition,
because the coadministration of TDF with a bPI has been
shown to increase the risk of nephrotoxicity and impair renal
function [18–20], we excluded all patients who were receiving
a bPI-based regimen. Because ABC was often prescribed to pa-
tients with renal dysfunction at baseline, including these pa-
tients could have introduced some degree of confounding by
indication. To minimize this potential effect, we conducted sec-
ondary analyses that excluded patients receiving ABC.
Serum creatinine concentration was measured using the Cobas
Integra 400 Plus automated chemistry analyzer (Roche Diagnos-
tics) from 2007–2008, and the Olympus AU400 analyzer (Beck-
man Coulter Diagnostics) thereafter. Quality control of chemistry
analyzers was performed according to manufacturer recommen-
dations. We determined the estimated glomerular filtration rate
(eGFR) using the chronic kidney disease–epidemiology (CKD-
EPI) formula [21]. This method is considered more accurate
than the Cockroft-Gault and modification of diet in renal disease
(MDRD) equations for values >60 mL/min/1.73 m2 and has re-
cently been shown to be accurate in HIV-infected populations as
well [22]. In sensitivity analyses, we repeated the main analyses
using the MDRD and the Cockroft-Gault formulas. In line
with the Kidney Disease Outcomes Quality Initiative criteria
[23, 24], we categorized renal function as follows: normal,
eGFR ≥90 mL/min/1.73 m2; mild eGFR decrease, 60–89 mL/
min/1.73 m2; moderate eGFR decrease, 30–59 mL/min/1.73 m2;
and severe eGFR decrease, ≤29 mL/min/1.73 m2. Our outcomes
of interest were (1) renal function after 6 and 12 months of ART,
(2) the proportion of patients experience an episode of moderate
or severe eGFR decrease while receiving ART, and (3) death.
Statistical Analyses
Baseline characteristics of patients starting TDF- and non–
TDF-containing ART regimens were compared using χ2 and
Mann-Whitney tests. We compared the median change in
eGFR between patients receiving TDF and those not receiving
TDF after 6 and 12 months of ART, according to baseline renal
function category. To estimate the difference in renal function
over time between the 2 study groups, we used a multivariable
mixed-effects model (eGFR measurements within patients),
using a random intercept with unstructured covariance correla-
tion structure, stratified by baseline renal dysfunction category.
In the TDF and non-TDF groups, we compared the proportions
of patients with normal renal function or mild renal dysfunc-
tion at baseline who had an episode of moderate or severe
eGFR decrease at 6 or 12 months . Adjusted estimates were
obtained using a multivariable logistic regression model. We
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used a multivariable competing risk subdistribution model, de-
scribed by Fine and Gray [25], to compare mortality rates be-
tween the 2 groups, measuring time from the initiation of
first-line ART to the outcome of interest. Accounting for loss
to follow-up, defined as not returning to the health care facility
for >6 months, as a competing risk of death, limits the produc-
tion of biased results. All multivariable regression analyses were
adjusted for age, sex, calendar year, WHO stage, CD4 count,
and hemoglobin. Anemia was defined as severe (hemoglobin
<5.0 mmol/L [<8.0 g/dL]), moderate (5.0 to <6.2 mmol/L [8.0
to <10.0 g/dL] in women and 5.0 to <6.8 mmol/L [8.0 to
<11.0 g/dL] in men), mild (6.2 to <7.4 mmol/L [10.0 to <12.0
g/dL] in women and 6.8 to <8.1 mmol/L [11.0 to <13.0 g/dL] in
men), or none (≥7.4 mmol/L [≥12.0 g/dL] in women and ≥8.1
mmol/L [≥13.0 g/dL] in men). All statistical analyses were per-
formed using Stata software (version 12.1; StataCorp).
RESULTS
Baseline Characteristics
In this analysis, we included 62 230 HIV-infected adults who
started ART between January 2007 and February 2011.
Of these, 38 716 (62.2%) started a TDF-containing first-line
regimen (Table 1). Individuals receiving TDF started ART
with a more advanced stage of disease and were more likely
to receive EFV than those not receiving TDF. Patients not re-
ceiving TDF-containing regimens were more likely to be female
and to have started ART in earlier years. Age and hemoglobin
were similar across treatment groups. Overall, patients receiving
TDF were slightly more likely to have some degree of baseline
renal dysfunction than those not receiving TDF-containing
ART (16.7% vs 12.4%). However, the proportion of patients
with moderate or severe renal dysfunction was 2 times higher
in the non-TDF than in the TDF group (4.0% vs 1.9%). After
ART initiation 70.4% of patients receiving TDF and 84.9% of
those receiving non-TDF regimens had at least 1 repeated
creatinine measurement available after either 6 or 12 months
of ART.
Changes in Renal Function in Patients With No or Mild eGFR
Decrease at Baseline
Among patients who started ART with no renal dysfunction,
we observed a slight decline in renal function at both 6 and
Table 1. Baseline Characteristics of Study Population by ART Regimen
Characteristic
With TDF Without TDF
P Value(n = 38 716; 62.2%) (n = 23 514; 37.8%)
Female, No. (%) 21 891 (56.5) 16 542 (70.4) <.001
Age, median (IQR), y 34 (29–40) 32 (27–38) <.001
WHO stage III/IV, No. (%) 22 989 (59.4) 11 218 (47.7) <.001
BMI, median (IQR), kg/m2 19.7 (17.8–22.1) 20.8 (18.5–22.6) <.001
CD4 count, median (IQR), cells/μL 151 (82–223) 172 (98–251) <.001
Missing, No. (%) 2333 (6.0) 1858 (7.9)
Anemia, No. (%) <.001
None 10 050 (26.0) 5650 (24.0)
Mild 13 291 (34.3) 8486 (36.1)
Moderate 9709 (25.1) 5429 (23.1)
Severe 3034 (7.8) 1760 (7.5)
Missing (%) 2632 (6.8) 2189 (9.3)
eGFR decrease, No. (%) <.001
None 32 247 (83.3) 20 621 (87.7)
Mild 5741 (14.8) 1967 (8.4)
Moderate 616 (1.6) 676 (2.9)
Severe 110 (0.3) 246 (1.1)
Calendar year of ART start, No. (%) <.001
2007 3204 (8.3) 10 842 (46.1)
2008 10 155 (26.2) 4589 (19.5)
2009 12 319 (31.8) 4594 (19.5)
2010 12 110 (31.3) 3297 (14.0)
2011 928 (2.4) 192 (0.8)
EFV-based ART, No. (%) 23 367 (60.4) 3913 (16.6) <.001
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; EFV, efavirenz; eGFR, estimated glomerular filtration rate; IQR, interquartile range; TDF, tenofovir
disoproxil fumarate; WHO, World Health Organization.
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12 months, irrespective of ART regimen (−15 mL/min in the
TDF and −17 mL/min in the non-TDF group). There was no
change in renal function over time in those with a mild eGFR
decrease at baseline (Figure 1). In adjusted analyses, patients
receiving TDF had slightly reduced renal function at 6 and 12
months, compared with those receiving other ART regimens,
although differences were small (Table 2). The proportion of
patients with no or mild baseline renal dysfunction with an
incident episode of severe eGFR decrease at 6 or 12 months
was higher in the TDF group, though this difference was not
statistically significant (0.28% vs 0.20% [P = .26] at 6 months
and 0.24% vs 0.15% [P = .20] at 12 months). For the outcome
defined as incident episodes of moderate or severe eGFR de-
crease, the differences reached statistically significance; however,
the numbers remained low (1.90% in the TDF vs 1.27% in the
non-TDF group [P < .001] at 6 months and 1.84% vs 1.37%
[P = .02] at 12 months; Figure 2). In adjusted analyses, patients
receiving TDF were more likely to experience an episode of
moderate or severe renal dysfunction than those receiving
other regimens during the first year of ART (Table 2).
Figure 1. Crude change in renal function during antiretroviral therapy, by baseline renal function and treatment group. Abbreviations: CKD-EPI, chronic
kidney disease–epidemiology formula; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; TDF, tenofovir disoproxil fumarate.
Table 2. Comparison of Renal Outcomes and Mortality Rates Between Patients Starting Antiretroviral Therapy With or Without TDFa
Baseline eGFR Decrease
Difference in eGFR (95% CI), mL/min
Progression to Renal Dysfunction,
OR (95% CI)
Mortality, sHR (95% CI)At 6 mo At 12 mo Severe Moderate/Severe
None −8.64 (−9.40 to −7.88) −9.93 (−10.7 to −9.14) 3.09 (1.85–5.17) 3.11 (2.52–3.87) 1.22 (1.13–1.31)
Mild −4.55 (−6.42 to −2.68) −6.81 (−9.01 to −4.61) 5.27 (1.19–23.2) 2.43 (1.80–3.28) 0.82 (.68–.98)
Moderate −6.10 (−11.0 to −1.23) −5.37 (−10.9 to .14) 1.11 (.46–2.70) NA 0.79 (.58–1.07)
Severe 19.3 (2.29–36.20) 21.7 (4.33–39.10) NA NA 0.89 (.52–1.52)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; NA, not applicable; OR, odds ratio; sHR, subhazard ration; TDF, tenofovir disoproxil
fumarate.
a The comparison was done using the chronic kidney disease–epidemiology formula, with patients not receiving TDF serving as the reference group. All analyses are
adjusted for age, sex, calendar year, baseline World Health Organization stage, CD4 cell count, and anemia status.
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Changes in Renal Function in Patients With Moderate or Severe
eGFR Decrease at Baseline
Independent of treatment regimen, individuals with moderate
(n = 616) or severe (n = 110) renal dysfunction at baseline
showed an improvement in renal function during ART. This
included patents who received TDF despite severe renal failure
(+30 mL/min after 12 months; Figure 1). In adjusted analyses,
TDF was associated with marginally lower renal function at
1 year in individuals with baseline moderate renal dysfunction.
On the contrary, among patients with available data, TDF use
seemed to be associated with a higher eGFR during follow-up
for those with severe renal dysfunction at ART initiation
(adjusted difference, +21.7 mL/min; 95% confidence interval
[CI], 4.33–39.10 at 1 year; Table 2). Finally, the odds of progres-
sion from moderate to severe dysfunction were not increased
for patients starting a TDF-containing ART regimen (adjusted
odds ratio, 1.11; 95% CI, .46–2.70; Table 2).
Mortality
During a total follow-up of 111 972 person-years, 2405 deaths
(6.2%) were documented in the TDF group, and 1472 (6.3%)
in the non-TDF group; 27.4% and 20.7% of patients, respective-
ly, were lost to follow-up in each group. Overall, the degree of
renal dysfunction at ART initiation predicted mortality risk. For
instance, patients with severe renal dysfunction at baseline were
twice as likely to die during follow-up as those with normal
renal function (Table 3). In adjusted analyses stratified by base-
line renal function, individuals who started a TDF-containing
regimen with some degree of renal dysfunction were not more
likely to die during follow-up than those receiving other treat-
ment regimens (Table 2). Notably, there was no detectable
difference in mortality rates between patients receiving TDF
and those not receiving TDF and starting ART with a moderate
(adjusted subhazard ratio, 0.79; 95% CI, .58–1.07) or severe
(0.89; .52–1.52) eGFR decrease. Other important risk factors
for death were male sex, advanced clinical stage of disease,
low CD4 cell counts, and anemia (Table 3).
Sensitivity Analyses
First, when we repeated the analyses using the MDRD and
Cockcroft-Gault equations to measure eGFR, we found similar
results for all the baseline renal eGFR categories (Supplementa-
ry Table 1A and 1B). Independently of the formula used, mor-
tality and eGFR decrease during follow-up in patients receiving
TDF despite moderate or severe baseline eGFR decrease were
not higher than in patients receiving other regimens. Second,
of the patients in the non-TDF group, 1787 (7.6%) started tak-
ing ABC. Excluding these patients from our analyses did not
alter our results significantly (Supplementary Table 2).
DISCUSSION
In this large observational cohort of HIV-1–infected adults in
Zambia, TDF did not have a significant effect on renal function
changes or mortality rates in patients starting ART with mod-
erate or severe renal dysfunction. Among individuals with no or
mild eGFR decrease at baseline, those receiving TDF were more
likely to experience an episode of moderate or severe renal dys-
function within the first 12 months of ART than were patients
receiving other regimens; however, the overall occurrence of this
outcome was rare.
Fifteen percent of the patients included in our study had some
degree of renal dysfunction at ART initiation. This is lower than
the proportions reported in other studies from SSA [12, 13].
These differences might have been driven by the degree of immu-
nosuppression at ART start, which was less advanced in our
study compared with the 2 other reports. Recent improvements
in screening for coinfections associated with renal dysfunction,
the avoidance of nephrotoxic drugs, and the change in CD4
threshold for ART initiation are additional factors that could
explain this finding. The use of TDF is not recommended for pa-
tients with moderate or severe eGFR decrease according to most
international guidelines. The Zambian national guidelines state
that patients should start a TDF-containing regimen only if
their creatinine clearance is >50 mL/min or their absolute
serum creatinine level ≤120 µmol/L. Many clinicians use the ab-
solute creatinine value to determine the ART regimen for reasons
of convenience. As a result, TDF is sometimes prescribed to
patients with an absolute creatinine level ≤120 µmol/L but undi-
agnosed moderate or severe renal eGFR decrease, as was the case
for 726 patients (1.9%) receiving TDF in our analysis cohort.
Our study showed that kidney function in patients with se-
vere baseline eGFR decrease improved during the first year of
ART, a finding that was even more pronounced in those
Figure 2. Proportion of patients with no or mild renal dysfunction at
baseline developing a moderate or severe eGFR decrease on ART. Abbre-
viations: ART, antiretroviral therapy; eGFR, estimated glomerular filtration
rate; TDF, tenofovir disoproxil fumarate.
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receiving TDF. Although the causes of renal dysfunction in pa-
tients starting ART in SSA have not been thoroughly investigat-
ed, it is assumed that HIV-associated nephropathy plays an
important role in this setting [26]. As a consequence, even
ART regimens containing potentially nephrotoxic agents can
improve renal function in most of the patients with renal insuf-
ficiency. Similar to our findings, in a large cohort of American
HIV-infected veterans, preexisting renal disease did not seem to
worsen the effects of TDF [9]. Of the 3336 Development of An-
tiRetroviral Therapy in Africa trial patients included in the anal-
ysis of renal outcomes, only 237 (7.1%) had moderate and 7
(0.2%) had severe renal dysfunction at ART initiation
[12, 14]; however, a detailed analysis of renal change by ART
regimen was not performed for these patients [14]. In contrast,
our patients who started a TDF-containing regimen with a
moderate eGFR decrease were not more likely to experience
severe renal dysfunction during ART than those receiving
other regimens. As expected, mortality rates increased with
worsening baseline eGFR decrease at baseline. However, TDF
was not associated with higher mortality rates in patients with
moderate or severe renal dysfunction at baseline. Taken togeth-
er, these findings suggest that starting a TDF-containing
regimen despite preexisting renal disease may be less harmful
than previously thought.
In our study, patients who started ART with normal kidney
function seemed to experience a slow decline in renal function
during the first year, irrespective of ART regimen. It has been
shown that even though ART seems to slow decline in creati-
nine clearance, a degree of renal function loss seems inevitable,
even with durable viral suppression [27]. Therefore, ART may
only improve kidney function if it is HIV or hepatitis B related.
In line with recent publications from high-income countries
Table 3. Risk Factors for Mortality
Factor Crude sHR (95% CI) P Value Adjusted sHR (95% CI) P Value
TDF in regimen <.001 .001
No 1 1
Yes 1.13 (1.06–1.21) 1.14 (1.05–1.23)
Baseline eGFR decrease <.001 <.001
None 1 1
Mild 1.19 (1.09–1.31) 1.24 (1.12–1.37)
Moderate 2.52 (2.16–2.94) 1.80 (1.53–2.13)
Severe 3.77 (2.96–4.80) 2.00 (1.52–2.63)
Baseline CD4 count <.001 <.001
<50 cells/μL 1 1
50–199 cells/μL 0.46 (.42–.51) 0.60 (.56–.65)
>199 cells/μL 0.23 (.20–.26) 0.42 (.38–.47)
Anemia <.001 <.001
None 1 1
Mild 2.06(1.78–2.39) 1.63 (1.45–1.83)
Moderate 3.82 (3.32–4.40) 2.70 (2.41–3.03)
Severe 5.93 (1.78–2.39) 3.88 (3.40–4.43)
Age (in years) 1.01 (1.00–1.01) <.001 1.01 (1.01–1.01) <.001
Sex <.001 <.001
Male 1 1
Female 0.81 (.75–.88) 0.77 (.72–.83)
WHO stage <.001 <.001
I or II 1 1
III 2.34 (2.13–2.58) 1.77 (1.62–1.93)
IV 2.56 (2.21–2.97) 2.12 (1.86–2.41)
Calendar year at ART start <.001 <.001
2007 1 1
2008 0.90 (.80–1.02) 0.94 (.86–1.02)
2009 0.76 (.67–.85) 0.71 (.64–.78)
2010 0.30 (.26–.34) 0.49 (.43–.55)
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; eGFR, estimated glomerular filtration rate; sHR, subhazard ratio; TDF, tenofovir disoproxil fumarate;
WHO, World Health Organization.
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that linked TDF with acute and chronic kidney dysfunction [8–
10, 14], patients receiving TDF in our analysis experienced more
pronounced reductions in renal function than those receiving
non-TDF regimens. Furthermore, we observed a 2-fold increase
in incident moderate or severe eGFR decreases in the TDF
group. However, the numbers remained small, with <1% of pa-
tients experiencing an episode of severe renal dysfunction
(eGFR < 30 mL/min) 6 or 12 months after ART initiation.
Our findings show that the overall effect of TDF on renal out-
comes in patients with normal baseline renal function is small.
Considering the low magnitude or even the absence of this as-
sociation in many previous reports [27, 28] and given the many
advantages related to the use of TDF, poor access to renal func-
tion monitoring may not be a good justification for withholding
TDF in first-line ART.
To our knowledge, this is the largest study assessing the
association between TDF and renal dysfunction in SSA to date.
We provide evidence on the safety of TDF-containing regimens
in a nonselected population with highly prevalent kidney dys-
function. Whereas many studies have examined the renal safety
of TDF in patients with normal baseline renal function, ours pro-
vides a detailed description of renal outcomes and mortality rates
in patients who received TDF despite preexisting eGFR decrease.
Our main limitation was the significant proportion of pa-
tients who did not have a follow-up creatinine measurement
(24.1%). Although we cannot exclude the nonrandom selection
of patients in whom at least 1 measurement was performed, it is
important to note that a significant proportion of individuals
receiving TDF were also missing creatinine measurements,
which reflects the situation of most ART programs in southern
Africa. Although it is common practice to report renal out-
comes as chronic kidney disease, defined as 2 eGFR measure-
ments <60 mL/min ≥3 months apart, such diagnoses may be
difficult in resource-constrained settings such as Zambia,
where follow-up testing is not always routinely performed.
For this reason, we were unable to further distinguish between
acute and chronic renal conditions. Because single drug
substitutions were not considered in our analyses, a fraction
of the patients who developed renal dysfunction while receiving
TDF might have been switched to a non–TDF-containing
regimen, which might have had an effect on our mortality
and severe eGFR decrease estimates. Some level of confounding
by treatment allocation was also possible, because the patients
included in this study were not randomized to receive either
TDF or non-TDF regimens. Therefore, we adjusted our analyses
for differences in baseline demographic and clinical character-
istics. Finally, we could not evaluate long-term renal outcomes,
and, because creatinine was the only routine measurement of
renal function performed in this cohort, we could not assess
the mechanisms of renal disease, such as proximal tubulopathy,
which has been associated with the use of TDF [29].
In summary, in our analysis of a large observational cohort in
Zambia, we show that patients receiving TDF-containing ART,
despite preexisting renal disease, did not experience worse renal
outcomes or increased mortality compared with those taking
other regimens. Baseline screening of renal dysfunction should
be encouraged, because dose adjustment of several antiretroviral
agents is recommended in case of eGFR decrease. However, our
data support the view that poor availability of renal function
screening should not stop the prescription of TDF-containing
ART, considering its numerous advantages over other combina-
tions. Studies monitoring and evaluating the long-term effect of
TDF in HIV-infected population in SSA are urgently needed.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data
provided by the author that are published to benefit the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We thank all study participants and staff of all
participating sites
Author contributions. L. M., B. H. C., and G. W. designed the
study. L. M., P. M., and G. W. performed the statistical analyses. L. M.,
P. M., and G. W. wrote the first draft of the manuscript. All authors contrib-
uted to the interpretation of the results and to the final version of the
manuscript. L. M., P. M., and G. W. had full access to all of the data
in the study and take responsibility for the integrity of the data and the
accuracy of the data analysis. M. A. D. is coprincipal investigator of
IeDEA-Southern Africa.
Financial support. This study was supported by the National Institutes
of Health, through the IeDEA Southern Africa collaboration (grant
1U01AI069924) and through research training programs (grants
R25TW009340 and D43TW001035). O. K. was supported by a PROSPER
fellowship grant from the Swiss National Science Foundation (nr
32333B_150934). The funders had no role in study design, data collection
and analysis, the decision to publish, or the preparation of the manuscript.
Potential conflicts of interests. All authors: No reported conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the
content of the manuscript have been disclosed.
References
1. Ministry of Health, Zambia. 2007 Antiretroviral therapy protocols.
Outprint Press, Lusaka, 2007.
2. Kilani B, Ammari L, Marrakchi C, et al. Seroepidemiology of HCV-HIV
coinfection in Tunisia. Tunis Med 2007; 85:121–3.
3. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine,
and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
N Engl J Med 2006; 354:251–60.
4. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus
dynamics in HIV-hepatitis B virus-co-infected patients treated with
tenofovir disoproxil fumarate. AIDS 2005; 19:907–15.
5. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir
disoproxil fumarate for the treatment of HIV infection in adults: the
first 4 years. AIDS 2007; 21:1273–81.
HIV/AIDS • CID 2014:58 (15 May) • 1479
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M.
Systematic review and meta-analysis: renal safety of tenofovir disoproxil
fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496–505.
7. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function
associated with tenofovir disoproxil fumarate treatment, compared with
nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis
2005; 40:1194–8.
8. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate,
chronic kidney disease and antiretroviral drug use in HIV-positive
patients. AIDS 2010; 24:1667–78.
9. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with
kidney disease risk in HIV infection. AIDS 2012; 26:867–75.
10. Laprise C, Baril JG, Dufresne S, Trottier H. Association between teno-
fovir exposure and reduced kidney function in a cohort of HIV-positive
patients: results from 10 years of follow-up. Clin Infect Dis 2013;
56:567–75.
11. Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with
a reduction in calculated glomerular filtration rates in the Swiss HIV
Cohort Study. Antivir Ther 2007; 12:1165–73.
12. Reid A, Stohr W, Walker AS, et al. Severe renal dysfunction and risk
factors associated with renal impairment in HIV-infected adults in Af-
rica initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271–81.
13. Mulenga LB, Kruse G, Lakhi S, et al. Baseline renal insufficiency and
risk of death among HIV-infected adults on antiretroviral therapy in
Lusaka, Zambia. AIDS 2008; 22:1821–7.
14. Stohr W, Reid A, Walker AS, et al. Glomerular dysfunction and associ-
ated risk factors over 4–5 years following antiretroviral therapy initia-
tion in Africa. Antivir Ther 2011; 16:1011–20.
15. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy
at primary care sites in Zambia: feasibility and early outcomes. JAMA
2006; 296:782–93.
16. Fusco H, Hubschman T, Mweeta V, Chi B, Levy J, Sinkala M, Stringer J.
Electronic patient tracking supports rapid expansion of HIV care and
treatment in resource-constrained settings. In: Third IAS Conference
on HIV Pathogenesis and Treatment Rio de Janeiro. Brazil, 24–27
July 2005; Abstract MoPe112C37.
17. Egger M, Ekouevi DK, Williams C, et al. Cohort Profile: the internation-
al epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan
Africa. Int J Epidemiol 2012; 41:1256–64.
18. Young J, Schafer J, Fux CA, et al. Renal function in patients with HIV
starting therapy with tenofovir and either efavirenz, lopinavir or ataza-
navir. AIDS 2012; 26:567–75.
19. Ryom L, Mocroft A, Kirk O, et al. Association between antiretroviral
exposure and renal impairment among HIV-positive persons with nor-
mal baseline renal function: the D:A:D study. J Infect Dis 2013;
207:1359–69.
20. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK.
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coad-
ministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr
2006; 43:278–83.
21. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009; 150:604–12.
22. Inker LA, Wyatt C, Creamer R, et al. Performance of creatinine
and cystatin C GFR estimating equations in an HIV-positive
population on antiretrovirals. J Acquir Immune Defic Syndr 2012;
61:302–9.
23. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Ann Intern Med 2003; 139:137–47.
24. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and
prognosis of chronic kidney disease: a KDIGO Controversies Confer-
ence report. Kidney Int 2011; 80:17–28.
25. Fine JP, Gray R. A proportional hazards model for the subdistribution
of a competing risk. J Am Stat Assoc 1999; 94:496–509.
26. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South
African perspective. Kidney Int 2006; 69:1885–91.
27. Leport C, Bouteloup V, Rossert J, et al. Long-term evolution and deter-
minants of renal function in HIV-infected patients who began receiving
combination antiretroviral therapy in 1997–1999, ANRS CO8 APRO-
CO-COPILOTE. Clin Infect Dis 2009; 49:1950–4.
28. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir
disoproxil fumarate-containing highly active antiretroviral therapy reg-
imens is not observed more frequently: a cohort and case-control study.
J Acquir Immune Defic Syndr 2004; 37:1489–95.
29. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R,
Braden G. Tenofovir-associated acute and chronic kidney disease:
a case of multiple drug interactions. Clin Infect Dis 2006; 42:
283–90.
1480 • CID 2014:58 (15 May) • HIV/AIDS
